Business description
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.
Management board & Supervisory board
| CEO |
| Robert I. Blum |
| Management board |
| Sung Lee, Andrew Callos, Isaac Ciechanover, Steven M. Cook, YulyMae DiNapoli, Fady I. Malik, Christine Murray, Brett Pletcher, Prodromos Anthopoulos, Neila Benabadji, Ajay Chawla, Joseph Dagher, Erin Donnelly, Genie Dubuk, John Faurescu, Katia Finck, Stephen B. Heitner, John Jacoppi, Michael Jiresch, Scott R. Jordan, Sunil Karnawat, Daniel E. Kates, Stuart Kupfer, Kari K. Loeser, Jeff Lotz, Lisa Meng, Bradley P. Morgan, Anne N. Murphy, Richey Neuman, Elisabeth A. Schnieders, Eric Terhaerdt, Norma Tom, Megan Truong, Diane Weiser, Robert C. Wong, Matt Yang |
| Supervisory board |
| Robert I. Blum, Muna Bhanji, Santo J. Costa, Robert A. Harrington, John T. Henderson, Edward M. Kaye, B. Lynne Parshall, Wendell Wierenga, Nancy J. Wysenski |
Company data
| Name: |
Cytokinetics Inc. |
| Address: |
350 Oyster Point Boulevard South San Francisco,, CA 94080, USA |
| Phone: |
+1-650-624-3000 |
| Fax: |
- |
| E-mail: |
-
|
| Internet: |
www.cytokinetics.com |
| Industry: |
Biotechnology |
| Sector: |
Biotechnology |
| Sub sector: |
Biotechnology |
| End of financial year: |
12/31 |
| Free Float: |
98.66% |
| IPO date: |
4/29/2004 |
